{"filing":{"accession_number":"0001193125-26-341206","cik":"0001579428","ticker":"AXSM","company_name":"Axsome Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"axsm-20260810.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-20260810.htm"},"events":[{"id":26338,"run_id":23929,"accession_number":"0001193125-26-341206","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"Axsome issued a press release on August 10, 2026 announcing Q2 2026 financial results, disclosing total net product revenue of $218.4 million (46% YoY growth), with AUVELITY sales of $180.3 million (51% YoY growth), SUNOSI revenue of $35.8 million (20% YoY growth), SYMBRAVO revenue of $2.3 million, and a net loss of $51.3 million. The disclosure includes detailed commercial metrics, operating expenses, cash position, and forward-looking guidance on cash sufficiency.","company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27426,"accession_number":"0001193125-26-341206","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Axsome issued a press release on August 10, 2026 announcing its financial results for Q2 2026, disclosing total net product revenue of $218.4 million (46% YoY growth), AUVELITY sales of $180.3 million (51% YoY growth), SUNOSI revenue of $35.8 million (20% YoY growth), and a net loss of $51.3 million. The filing explicitly states this is furnished as Exhibit 99.1 pursuant to Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes detailed financial highlights, commercial metrics, and pipeline updates material to investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:06:48.337972+00:00","company_name":"","ticker":null,"filing_date":""},{"id":27427,"accession_number":"0001193125-26-341206","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 8.01 disclosure references an updated corporate presentation posted to the company's website, but the substantive content furnished as Exhibit 99.1 is a comprehensive earnings release for Q2 2026. The exhibit reports total net product revenue of $218.4 million (46% YoY growth), product-specific sales figures (AUVELITY $180.3M, SUNOSI $35.8M, SYMBRAVO $2.3M), operating expenses, net loss of $51.3 million, cash position, and forward-looking guidance on cash sufficiency. This is a standard quarterly earnings disclosure material to investors assessing the company's financial performance and operational trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:06:48.337972+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27426,"accession_number":"0001193125-26-341206","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Axsome issued a press release on August 10, 2026 announcing its financial results for Q2 2026, disclosing total net product revenue of $218.4 million (46% YoY growth), AUVELITY sales of $180.3 million (51% YoY growth), SUNOSI revenue of $35.8 million (20% YoY growth), and a net loss of $51.3 million. The filing explicitly states this is furnished as Exhibit 99.1 pursuant to Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes detailed financial highlights, commercial metrics, and pipeline updates material to investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:06:48.337972+00:00","company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","filing_date":"2026-08-10"},{"id":27427,"accession_number":"0001193125-26-341206","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 8.01 disclosure references an updated corporate presentation posted to the company's website, but the substantive content furnished as Exhibit 99.1 is a comprehensive earnings release for Q2 2026. The exhibit reports total net product revenue of $218.4 million (46% YoY growth), product-specific sales figures (AUVELITY $180.3M, SUNOSI $35.8M, SYMBRAVO $2.3M), operating expenses, net loss of $51.3 million, cash position, and forward-looking guidance on cash sufficiency. This is a standard quarterly earnings disclosure material to investors assessing the company's financial performance and operational trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:06:48.337972+00:00","company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","filing_date":"2026-08-10"}]}